Forward Looking Statement This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation,

Developing Innovative Therapies to Address Rare Diseases and Underserved NASDAQ: OCGN Eye Corporate Deck

Forward Looking Statement This presentation contains forward-looking statements that involve substantial

risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements

regarding our business strategy, future results of operations and financial position, prospective products, product approvals,

research and development costs, timing and likelihood of success, estimated market size or growth, and plans and objectives of

management for future operations, are forward-looking statements. When used in this presentation, the words "anticipate,"

"believe," "contemplate," "continue," "could," "estimate," "expect,"

"intend," "may," "plan," "potential," "predict," "project,"

"should," "target," "would," and similar expressions are intended to identify forward-looking

statements, although not all forward-looking statements contain these identifying words. Forward-looking statements involve known

and unknown risks, uncertainties and other factors, including those risks set forth in the Company's filings with the Securities

and Exchange Commission, which are available at www.sec.gov, that may cause our actual results, performance or achievements to

be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

Forward-looking statements are based on our management's beliefs and assumptions and on information available to management

as of the date of this presentation. Our actual future results may be materially different from what we expect. Except as required

by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could

differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

This presentation includes estimates by us of statistical data relating to market size and growth and other estimated data about

our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such

estimates. This presentation also includes statistical and other industry and market data that we obtained from industry publications

and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies

generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee

the accuracy or completeness of such information. While we believe these industry publications and third-party research, surveys

and studies are reliable, we have not independently verified such data. This communication shall not constitute an offer to sell

or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities

in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the

securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements

Company Highlights Nasdaq-listed company as of September 30, 2019 Robust IP portfolio with 31 issued U.S.

and foreign patents and 29 U.S. and foreign patent applications Strategic Partnership with CanSinoBIO for OCU400 Gene Therapy Co-Development

for ocular Graft Versus Host Disease (oGVHD) Orphan Drug Designation MODIFIER GENE THERAPY PLATFORM OCU400 for Inherited Retinal

Diseases - Orphan Drug Designations (NR2E3 and CEP290 Mutation-Associated Retinal Diseases) OCU410 for Dry AMD NOVEL BIOLOGIC

THERAPIES FOR RETINAL DISEASES OCU200 for Wet AMD, Diabetic Macular Edema, Diabetic Retinopathy OCU100 for Retinitis Pigmentosa

Experienced Leadership Team - - - Diverse experience in large pharma, signature biotech,

and small companies Track record of success Brings large and small company learnings to Ocugen 4 2019 Ocugen. All Rights

Reserved. Rasappa Arumugham, PhD Chief Scientific Officer Vijay Tammara, PhD Vice President, Regulatory & Quality Kelly Beck,

MBA Vice President, Investor Relations & Administration Daniel Jorgensen, MD, MPH, MBA Chief Medical Officer Sanjay Subramanian,

MBA Chief Financial Officer Shankar Musunuri, PhD, MBA Chairman, CEO and Co-Founder

Orphan us oGVHD 60,000 OCU300 NR2E3 Mutation-Associated RetinalDegeneration Orphan us 500-600 CEP290 Mutation-Associated

RetinalDegeneration Orphan us OCU400 NR2E3-MV 2,500-3,000 Rhodopsin Mutation-Associated RetinalDegeneration 10,400-12,700 OCU410

RORA-MV 9-10M Dry AMD > WetAMD 1.1M > > OCU200 Tumslatin-Transferrin 745,000 Diabetic Macular Edema Diabetic Retinopathy

OCU100 Retinitis Pigmentosa Gene Therapy Pricing Reference: Novartis gene therapy Zo/gensma = $2.1M per patient Source: The

Wall Street Journal, October 22, 2019 , ocugen 5 @2019 Ocusen.AII Rishts Reserved. RETINAL DISEASES (novel biologics) MODIFIER

GENE THERAPY PLATFORM OCULAR SURFACE DISEASE (small molecule) Phase 2 Phase 3 Phase 1 Preclinical Prevalence (US) Indication

OCU300 for oGVHD: Unmet Need for Patients with Ocular Graft vs Host Disease (oGVHD) Rare Ocular Diseases

~60% of allogeneic bone marrow transplant patients will develop oGVHD - Autoimmune disease that occurs in allogeneic bone

marrow transplant (BMT) patients -Donor derived leukocytes attack recipient ocular tissue Patients encounter dry, tearless

eyes, vision issues, severe pain, discomfort, and potential ocular scarring May lead to significant vision loss and irreparable

ocular surface damage ~63,000 patients in the US by 2020 - - ~3-6 months from transplant is when patients will develop

Hematopoietic Cell Transplant Survivors in the United States, Majhail N et al Oct 2014 Source: https://bethematch.org/tcdirectory/search/advanced/#-/-/-/false/-/TotalTransplants-Ocugen

is the first and only company to receive orphan drug designation from FDA for treatment of oGVHD

First Phase 3 Study With Orphan Drug Designation Indication: Treatment of ocular discomfort and ocular

redness in patients with oGVHD - - 84-day, Randomized, Double-Masked, Placebo-Controlled Study Key inclusion criteria:

diagnosis of definite' oGVHD using the International Chronic Ocular GVHD Consensus Group revised diagnostic criteria

(Ogawa, 2013) Patients referred to specialty BMT centers; 10+ centers are active in this study - 2:1 randomization (OCU300

n=40; Placebo n=20) Co-primary endpoints include: -Symptom: Ocular discomfort based on Visual Analog Scale (VAS) On a scale

from 0-10, what was the intensity of your Ocular Discomfort, at its worst, over the past 24 hours? - Sign: Ocular redness

OCUO3C0U0300 (Brimonidine 0.18% OcuNanoE ) PLAPCLEABCOE*BO (Ophthalmic Buffered Saline)

Brimonidine Safety Existing Molecule is already proven safe and effective Efficacy Early stage clinical

studies led to Phase 3 design OcuNanoE drug delivery system improves overall efficacy - 505(b)(2) regulatory pathway

allows use of safety data already available for brimonidine OCU300 is preservative-free (no BAK) - Brimonidine approved for

Generic substitution prohibited - Generic brimonidine (0.2%) not approved for oGVHD - Concentration/formulation different

from OCU300 - Contains BAK preservative - OCU300 completing controlled studies in oGVHD patients - AB criteria not

OcuNanoETM Drug Delivery System Improves Overall Efficacy Brimonidine Level in Lacrimal Gland (Preclinical)

Mouse DED Model (Preclinical) ** 1 0 0 0 4 3 1 0 0 2 1 0 1 0 3 6 9 1 2 0 Drug distribution to lacrimal gland from traditional eye

drops is low relative to other target tissues T i m e ( h ) O C U 3 0 0 B r i m o n i d i n e T M O C U 3 0 0 ( 0 . 1 8 % ) O c

u N a n o E - - - OCU300 = Brimonidine (0.18%) OcuNanoE Brimonidine = Commercial 0.2% solution Figure shows

median, interquartile range & min/max fluorescein score **p<0.01 B r i m o n i d i n e s o l u t i o n ( 0 . 2 % ) -

u o r e s c e i n S c o r e OcuNanoE increases brimonidine in lacrimal gland and improves overall efficacy of OCU300

OCU300 has Compelling Value Proposition Market Access Market Potential Physicians Patients - Spend

3 months in hospital after receiving bone marrow transplant - Potential to be first approved product in US market - Most

exhibit symptoms while still under hematologist/ oncologist care - First and only company to receive Orphan Drug Designation

from FDA for oGVHD - Advances in hematopoietic cell transplantation leading to increasing number of transplant survivors ~63,000

then referred to specialized ophthalmologists - Hematologists looking for approved therapy; no knowledge of off-label options

- No approved therapy - Seek to establish ICD-10 diagnostic code - Analysis supports premium pricing - Opportunities

to partner for commercialization Targeted BMT Centers Premium Pricing

Modifier Gene Therapy Platform 12

Modifier Gene Therapy Has a Broader Impact of diseases using the same gene(s) other than modifier gene

the expression of many genes, gene-networks and reset homeostasis. ModifierWe can address a number gene MModifier Gene product.

Cell Cell Cell Cell with mutated/nonfunctioningCell with OCU400 Novel approach that targets nuclear hormone genes (NHRs), which

regulate multiple functions within the retina Smoother regulatory pathway due to ability to target multiple diseases with one Ability

to recoup development costs over multiple therapeutic indications NR2E3 Mutation-Associated Retinal Disease CEP290 Mutation-Associated

Retinal Disease Rhodopsin Mutation-Associated Retinal Disease GENE X GENE X GEN E M GENE M Gene Augmentation: Transfer functional

version of a non-functional gene into the target cells. Normal gene X Cell Cell Cell Cell with mutated/ nonfunctioning gene X Traditional

Gene Therapy Traditional approach that targets one individual gene mutation at a time Regulatory pathway focused on specific product

for one disease Longer time to recoup development costs ONE Disease GENE X GENE X GENE X GEN E X GEN E X GENE X

OCU400 (NR2E3) Rescues Vision Loss in Multiple Inherited Human Disease: Retinal Diseases (IRDs) Rhodopsin

associated adRP Rho-/-Rhodopsin associated adRP RhoP23 H PDE6B associated RP rd1-/-PDE associated arRP rd10-/-Leber Congenital

Amaurosis Cep290 (rd16) Mouse Models: ^ *Treated fundus photos: subretinal single injection Control Retinal Degeneration Mice Models

Product Rescues Multiple IRDs after onset

OCU400: Orphan Drug Designation NR2E3 Mutation-Associated Retinal Degeneration Early stage disease OCU400

Single Injection (Intravitreal) 1 mo Baseline (Control) 1 mo after treatment Advanced stage disease OCU400 Single Injection (Intravitreal)

3 mo Baseline (Control) 1 mo after treatment 3 mo Baseline (Control) 1 mo after treatment OCU400 Single Injection (Subretinal)

Gene Therapy Manufacturing: A Major Bottleneck Faced by All Increased demand for cell & gene therapy

manufacturing - - 1,060 clinical trials globally; 80 cell and gene therapy trials in Phase 3 Large pharma acquiring companies

to support internal programs - eg: Roche acquired Spark; Pfizer acquired Bamboo; Celgene acquired Juno Others being acquired

by major CMOs to establish their presence in the gene therapy - eg: Thermo Fisher acquired Brammer Bio; Catalent acquired

Paragon - Gene therapy companies facing manufacturing bottleneck & costs - - - Long wait in the queue for

CMO while large pharma can bypass (due to scope and financial power) Traditional CMO model not appropriate for implementing specialized

process optimization steps High cost for the CMC development and clinical supplies; approximately: - - - $7M

- $10M for Phase 1 $8M - $10M for late stage $10M - $15M for scale-up development for commercialization/BLA filing 16 2019